HAEMONETICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.99 USD | +3.80% |
|
+12.00% | +6.41% |
| Apr. 04 | Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge | MT |
| Apr. 04 | Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge | CI |
Financials (USD)
| Sales 2024 * | 1.3B | Sales 2025 * | 1.37B | Capitalization | 4.62B |
|---|---|---|---|---|---|
| Net income 2024 * | 126M | Net income 2025 * | 158M | EV / Sales 2024 * | 4.03 x |
| Net Debt 2024 * | 595M | Net Debt 2025 * | 508M | EV / Sales 2025 * | 3.73 x |
| P/E ratio 2024 * |
36.5
x | P/E ratio 2025 * |
27.9
x | Employees | 3,034 |
| Yield 2024 * |
2.2% | Yield 2025 * |
2.2% | Free-Float | 99.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Haemonetics Corporation
More recommendations
More press releases
| 1 day | +3.80% | ||
| 1 week | +12.00% | ||
| Current month | +6.61% | ||
| 1 month | +8.21% | ||
| 3 months | +11.92% | ||
| 6 months | +7.62% | ||
| Current year | +6.41% |
1 week
80.90
91.58
1 month
80.1591.58
Current year
70.7491.58
1 year
70.7495.26
3 years
43.5095.26
5 years
43.50142.11
10 years
25.98142.11
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | 16-05-15 | |
James D'Arecca
DFI | Director of Finance/CFO | 53 | 22-04-10 |
Jan Hartmann
CTO | Chief Tech/Sci/R&D Officer | - | 06-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Abernathy
BRD | Director/Board Member | 69 | 17-10-17 |
| Director/Board Member | 69 | 14-07-22 | |
Ellen Zane
CHM | Chairman | 72 | 18-01-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.28% | 45 M€ | +0.20% | ||
| 0.14% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 90.99 | +3.80% | 749,023 |
| 24-04-25 | 87.66 | +1.67% | 431,158 |
| 24-04-24 | 86.22 | +1.35% | 238,823 |
| 24-04-23 | 85.07 | +1.73% | 231,275 |
| 24-04-22 | 83.62 | +2.93% | 402,130 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotes
Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.
Calendar
2024-05-09
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
90.99
USD
Average target price
104.9
USD
Spread / Average Target
+15.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.41% | 4.62B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- HAE Stock
